Genentech Enters into an Exclusive Worldwide Collaboration and Option to Acquire Agreement with Convelo to Discover Remyelinating Therapies

Shots:

• Genentech & Convelo collaborate to discover and develop remyelination therapies for patients with neurological disorders including multiple sclerosis
• Convelo to receive up front and research support from Genentech. Genentech to retain an exclusive option to acquire Convelo in all-stock transaction for additional payment and downstream milestones
• Remyelinating therapies are involved in unlocking the regenerative capacity of the CNS by generating the protective myelin coating around nerve cells for neurological diseases like MS, pediatric leukodystrophies, traumatic injury and Alzheimer’s

Click here to read full press release/ article | Ref: Convelo | Image: Convelo